secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001104659-24-057525
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio CEO letter details Phase II/III AD data; will narrow enrollment to early-stage patients for next trial
--------------------------------------------------------------------------------

- Phase II/III study in MMSE 21-24 patients: buntanetap showed ADAS-Cog11 improvement of -2.36 vs placebo at 3 months.
- In moderate AD (MMSE 14-20), improvement was -0.65 vs placebo +1.79, indicating high placebo effect.
- Next Phase III will prescreen for plasma AD biomarkers and enroll only early/mild AD (MMSE 21-28).
- CEO states FDA will accept buntanetap for symptomatic relief and allow continuation for disease-modification study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924057525/0001104659-24-057525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924057525/tm2413238d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-057525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer